theory clinical_104_2
imports Main

begin

typedecl entity
typedecl event

consts
  Inhibitor :: "entity ⇒ bool"
  Irreversible :: "entity ⇒ bool"
  TargetedTo :: "entity ⇒ entity ⇒ bool"
  HER2KinaseDomain :: "entity ⇒ bool"
  Overcome :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  TrastuzumabResistance :: "entity ⇒ bool"
  InducedBy :: "entity ⇒ event ⇒ bool"
  HER2ActivatingMutation :: "event ⇒ bool"
  HER2V777L :: "entity ⇒ bool"
  Resistance :: "entity ⇒ bool"
  Trastuzumab :: "entity ⇒ bool"
  Cause :: "event ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  ExtracellularKinaseDomain :: "entity ⇒ bool"
  Binds :: "event ⇒ bool"
  Mutation :: "entity ⇒ bool"
  IntracellularKinaseDomain :: "entity ⇒ bool"
  In :: "entity ⇒ entity ⇒ bool"
  Targeting :: "entity ⇒ bool"
  HERV777LMutation :: "entity ⇒ bool"
  TyrosineKinaseInhibitor :: "entity ⇒ bool"
  CausedBy :: "entity ⇒ event ⇒ bool"
  HER2V777LMutation :: "event ⇒ bool"
  TreatmentResistance :: "event ⇒ bool"

(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)
axiomatization where
  explanation_1: "∃x y z e1 e2. Inhibitor x ∧ Irreversible x ∧ TargetedTo x y ∧ HER2KinaseDomain y ∧ Overcome e1 ∧ Agent e1 x ∧ TrastuzumabResistance z ∧ InducedBy z e2 ∧ HER2ActivatingMutation e2"

(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)
axiomatization where
  explanation_2_1: "∃x y e. HER2V777L x ∧ Resistance y ∧ Trastuzumab y ∧ Cause e ∧ Agent e x ∧ Patient e y"

axiomatization where
  explanation_2_2: "∃x y e. Trastuzumab x ∧ ExtracellularKinaseDomain y ∧ Binds e ∧ Agent e x ∧ Patient e y"

axiomatization where
  explanation_2_3: "∃x y. Mutation x ∧ IntracellularKinaseDomain y ∧ In x y"

(* Explanation 3: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can overcome the resistance caused by the HER2 V777L mutation. *)
axiomatization where
  explanation_3: "∃x y z e1 e2. Targeting x ∧ HERV777LMutation y ∧ TyrosineKinaseInhibitor x ∧ Irreversible x ∧ Overcome e1 ∧ Agent e1 x ∧ Resistance z ∧ CausedBy z e2 ∧ HER2V777LMutation e2"

(* Explanation 4: Overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)
axiomatization where
  explanation_4: "∀x y e1 e2. Resistance x ∧ HER2V777LMutation y ∧ CausedBy x y ∧ Overcome e1 ∧ Agent e1 x ⟶ (Overcome e2 ∧ TreatmentResistance e2)"

theorem hypothesis:
  assumes asm: "HERV777LMutation y ∧ TreatmentResistance e"
  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)
  shows "∃x y e. Targeting x ∧ HERV777LMutation y ∧ TyrosineKinaseInhibitor x ∧ Irreversible x ∧ Overcome e ∧ Agent e x ∧ Patient e y ∧ TreatmentResistance e"
proof -
  (* From the known information, we have HERV777LMutation y and TreatmentResistance e. *)
  from asm have "HERV777LMutation y ∧ TreatmentResistance e" by auto
  (* Explanation 3 provides that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can overcome the resistance caused by the HER2 V777L mutation. *)
  (* This is represented by the logical relation Implies(F, G). *)
  (* Explanation 4 states that overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance, represented by Implies(G, H). *)
  (* Therefore, from F, we can infer H. *)
  then have "∃x y e. Targeting x ∧ HERV777LMutation y ∧ TyrosineKinaseInhibitor x ∧ Irreversible x ∧ Overcome e ∧ Agent e x ∧ Patient e y ∧ TreatmentResistance e" sledgehammer
  then show ?thesis <ATP>
qed

end
